Spiro-Azetidine Oxindoles as Long-Acting Injectables for Pre-Exposure Prophylaxis against Respiratory Syncytial Virus Infections
Journal of Medicinal Chemistry · 2024
DOI: 10.1021/acs.jmedchem.4c00514 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Bart Kesteleyn und 26 weiteren Autor:innen. Beteiligte Einrichtung: Janssen Research & Development, Janssen Pharmaceutica NV, Turnhoutseweg 30, Beerse 2340, Belgium. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Infections, Oxindoles, Spiro Compounds, Antiviral Agents. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Janssen Pharmaceutica.
Abstract (Originalsprache)
Respiratory syncytial virus (RSV) is a major cause of hospitalization in infants, the elderly, and immune-compromised patients. While a half-life extended monoclonal antibody and 2 vaccines have recently been approved for infants and the elderly, respectively, options to prevent disease in immune-compromised patients are still needed. Here, we describe spiro-azetidine oxindoles as small molecule RSV entry inhibitors displaying favorable potency, developability attributes, and long-acting PK when injected as an aqueous suspension, suggesting their potential to prevent complications following RSV infection over a period of 3 to 6 months with 1 or 2 long-acting intramuscular (IM) or subcutaneous (SC) injections in these immune-compromised patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Janssen Research & Development, Janssen Pharmaceutica NV, Turnhoutseweg 30, Beerse 2340, Belgium.
- Janssen Research & Development, 1400 McKean Rd, Spring House, Pennsylvania 19477, United States.
ORCID-Profile: Bart Kesteleyn, Kiran Matcha, Morgan Lecomte, Samuel Demin, Tim H M Jonckers
Förderung
- Janssen Pharmaceutica
Zitieren
APA
Kesteleyn, B., Herschke, F., Darville, N., Stoops, B., Jacobs, T., Jacoby, E., Shaffer, P., Lammens, L., Van Rompaey, D., Matcha, K., Martinez Lamenca, C., Coesemans, E., Hache, G., Pieters, S., Lecomte, M., Hu, L., Demin, S., Milligan, C., Abeywickrema, P., …, & Jonckers, T. H. M. (2024). Spiro-Azetidine Oxindoles as Long-Acting Injectables for Pre-Exposure Prophylaxis against Respiratory Syncytial Virus Infections. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c00514
Vancouver
Kesteleyn B, Herschke F, Darville N, Stoops B, Jacobs T, Jacoby E, et al. Spiro-Azetidine Oxindoles as Long-Acting Injectables for Pre-Exposure Prophylaxis against Respiratory Syncytial Virus Infections. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.4c00514
BibTeX
@article{Kesteleyn2024,
author = {Kesteleyn, Bart and Herschke, Florence and Darville, Nicolas and Stoops, Bart and Jacobs, Tom and Jacoby, Edgar and Shaffer, Paul and Lammens, Lieve and Van Rompaey, Dries and Matcha, Kiran and Martinez Lamenca, Carolina and Coesemans, Erwin and Hache, Geerwin and Pieters, Serge and Lecomte, Morgan and Hu, Lili and Demin, Samuel and Milligan, Cynthia and Abeywickrema, Pravien and De Bruyn, Suzanne and Van Den Berg, Joke and Ysebaert, Nina and De Zwart, Loeckie and Nájera, Isabel and Rigaux, Peter and Roymans, Dirk and Jonckers, Tim H M},
title = {Spiro-Azetidine Oxindoles as Long-Acting Injectables for Pre-Exposure Prophylaxis against Respiratory Syncytial Virus Infections},
journal = {Journal of Medicinal Chemistry},
year = {2024},
doi = {10.1021/acs.jmedchem.4c00514}
}
EUVIMED